Health Canada's Special Access Program: What Drug Sponsors and Manufacturers Actually Need to Know

A physician in Manitoba has a pediatric patient with refractory epilepsy. Every approved Canadian therapy has failed or is contraindicated. There’s a drug available in the US and approved by the FDA, but no Notice of Compliance (NOC) has ever been issued in Canada. Her next step isn’t a compassionate use trial enrollment. It’s a submission to Health Canada’s Special Access Program.

That scenario plays out thousands of times each year across Canada. And while most of the regulatory attention in that story falls on the practitioner making the request, the compliance obligations it creates for manufacturers and drug sponsors are just as real — and considerably less discussed.

The SAP is governed by section C.08.010 of the Food and Drug Regulations (FDR), and it sits in a corner of Canadian regulatory law that CROs, CMOs, and drug sponsors often treat as someone else’s problem. It isn’t. Here’s what you need to understand before the first request hits your inbox.

What the Special Access Program Actually Is — and Isn’t

The SAP authorizes the sale of drugs not approved for sale in Canada — or drugs that are approved but currently unavailable — to practitioners treating patients with serious or life-threatening conditions where no suitable Canadian alternative exists. That framing matters, because the two conditions (“serious or life-threatening” and “no suitable alternative”) are both gatekeeping criteria that Health Canada’s reviewers apply with genuine scrutiny.

The SAP is not a soft pathway around the approval process. Authorizations are patient-specific, practitioner-submitted, and generally non-renewable without fresh medical justification. They don’t create a right to ongoing commercial supply. They don’t substitute for a drug master file or a New Drug Submission. And they don’t exempt the manufacturer from Good Manufacturing Practice requirements — a point we’ll return to.

What the SAP does do is provide a functional mechanism for individual patients to access drugs that would otherwise be legally unavailable to them. Health Canada’s SAP team operates year-round and handles a large volume of requests across drug categories including prescription drugs, radiopharmaceuticals, and — under a parallel track — medical devices. Cannabis is excluded and has separate exceptional access provisions. Veterinary drugs run through a distinct SAP stream.

For organizations in the CRO or CMO space, the SAP intersects with your operations in at least two practical ways. First, drugs your clients have under clinical development may be requested via SAP by practitioners treating patients who don’t qualify for, or can’t access, an active trial. Second, if you manufacture or import drugs for Canadian patients under any authorization, SAP shipments carry their own documentation and reporting obligations separate from your standard distribution records.

The Two Pathways: Regular SAP and Emergency Drug Release

There are two operationally distinct ways a practitioner accesses the program, and the distinction matters for how your organization needs to respond.

The Regular SAP is the standard non-emergency pathway. Since Health Canada modernized the portal in 2022, practitioners submit requests online, providing medical rationale, patient demographics, diagnosis, proposed dosing regimen, and confirmation that no suitable Canadian alternative is available. Health Canada targets a decision within 2 to 3 business days for complete requests. When an authorization is issued, Health Canada notifies both the practitioner and the identified manufacturer or importer simultaneously.

The Emergency Drug Release (EDR) pathway is different in urgency and character. It operates 24 hours a day, 7 days a week, including statutory holidays. A practitioner facing an immediately life-threatening situation can reach Health Canada’s EDR line by phone and receive a verbal authorization — sometimes within a few hours — with written documentation to follow. The EDR pathway exists precisely because patient deterioration doesn’t wait for business hours, and Health Canada’s SAP staff are trained to make clinical assessments under time pressure.

Here’s the operational gap that surprises a lot of manufacturers: Health Canada’s authorization notifies you that you’re permitted to supply — it does not compel supply, and it does not manufacture the drug into existence. If your organization doesn’t have an SAP contact registered with Health Canada, if your logistics team has never processed an SAP order, or if your inventory system doesn’t support lot-level SAP record-keeping, that authorization does nothing for the patient. Getting your infrastructure in place before the first request arrives isn’t optional; it’s part of what it means to have a drug in a market where the SAP pathway exists.

What Health Canada Evaluates — and Where Requests Stall

Understanding what Health Canada’s reviewers actually assess helps manufacturers anticipate how requests involving their drugs will be handled, and what documentation to have ready.

Reviewers focus on four areas:

Medical necessity and standard-of-care evidence. The practitioner must establish that existing approved therapies have failed, are contraindicated, or are otherwise genuinely unsuitable for this patient. Vague rationales are the most common reason requests slow down. Reviewers want to see clinical specificity: what was tried, at what dose, for how long, why it didn’t work.

Product information and regulatory standing. Health Canada looks at whether the drug is approved by a recognized reference authority — the US FDA, the European Medicines Agency (EMA), the UK’s MHRA, Australia’s TGA, or a comparable regulator. A drug with a full foreign label, a Summary of Product Characteristics, and known safety data gets a faster review than one supported only by published literature. Manufacturers who ensure their prescribing information and safety data are accessible to Health Canada’s reviewers — even informally — help themselves here.

Manufacturer willingness and ability to supply. This is where your organization becomes directly relevant to the reviewer’s decision. Health Canada will contact the named manufacturer or importer. If your organization has no SAP contact registered, no one answers, or your response is that you can’t ship to Canada, the authorization process stalls. Requests most commonly fail at this stage not because Health Canada denies them but because the supply side isn’t ready.

Patient population and indication plausibility. Off-label access for a completely unapproved indication in a population with no other options receives different scrutiny than a request for a drug that has an active foreign approval for precisely the indication described. Reviewers are clinically trained and evaluate the medical coherence of the request, not just its administrative completeness.

Manufacturer Obligations Under C.08.010 — The Requirements Most Companies Miss

If your organization ships a drug under an SAP authorization, section C.08.010 of the Food and Drug Regulations creates specific post-sale compliance obligations. These are binding regardless of your organization’s size or how infrequently SAP requests arrive.

Annual summary reports. Under C.08.010(4), manufacturers and importers must submit an annual report to Health Canada for each drug supplied via SAP. The report must include the total quantity supplied, the number of patients treated, the therapeutic indications, and any adverse reactions observed. This is not an internal summary for your own quality records — it goes to Health Canada. Late or missing annual reports are a compliance event, and Health Canada uses these reports to identify safety signals in drugs outside the formal post-market surveillance framework.

Lot-level shipment records. For every SAP shipment, you must maintain records of: the name and address of the requesting practitioner, the quantity shipped, the lot or batch number, and the date of shipment. Retain these for a minimum of 5 years — consistent with Drug Establishment Licence (DEL) record-keeping standards under the FDR. These records are subject to Health Canada inspection.

Adverse reaction reporting. An adverse reaction associated with an SAP drug is reportable to Health Canada under the same framework as any other drug. Serious and unexpected adverse reactions must be reported within 15 calendar days of becoming aware of them. The absence of a NOC creates no exemption from pharmacovigilance obligations once you’re supplying the drug.

GMP compliance. Health Canada expects SAP drugs to meet the same manufacturing quality standards as approved drugs intended for Canadian patients. If your facility or your CMO’s facility isn’t in good standing with Health Canada — or isn’t recognized under a Mutual Recognition Agreement with a comparable authority — that can affect whether an authorization will proceed. Contract manufacturers producing drugs that may be subject to SAP requests need to ensure their GMP standing is current.

In our work with Canadian CROs and pharmaceutical sponsors, this is the area where we most consistently see gaps: organizations that are fully GMP-compliant and well-prepared on the clinical side, but have never formalized their SAP response protocols or connected their quality management systems to the post-SAP reporting requirements.

Building SAP Readiness Before You Need It

The organizations that handle SAP requests well are those that built their infrastructure in advance, not in response to an incoming authorization. That means: a named SAP contact registered with the Health Canada portal; an internal SOP covering the full order cycle from authorization receipt to shipment to record entry; annual report triggers built into your QMS calendar; and clarity with your logistics and finance teams about how SAP orders are processed differently from standard commercial orders.

If your drug is approved in a major foreign jurisdiction, treats a serious or rare condition, or is currently in a Canadian clinical trial — any of those three factors substantially increases the probability that an SAP request will eventually arrive. Treating SAP readiness as a compliance checkbox rather than an operational discipline is the most predictable way to be caught flat-footed.

Canada’s Health Canada SAP framework is active, well-staffed, and highly functional. Understanding what it asks of you on the manufacturer side — section C.08.010 records, annual reports, adverse reaction reporting, GMP standing — is the foundation of being a responsible Canadian market participant, even for drugs that have never been formally approved for sale here.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• GMP-compliant analytical testing for Canadian drug submissions — ISO 17025-accredited laboratory services for pharmaceutical manufacturers and importers supporting DEL compliance and supplier qualification programs
• Navigating compassionate use and exceptional access in the EU — Regulatory guidance for manufacturers entering European markets under the EU’s named-patient and compassionate use frameworks